Barron's sees the biotech sector enjoying its strongest start to a new year in a decade, and...

|By:, SA News Editor
Barron's sees the biotech sector enjoying its strongest start to a new year in a decade, and this outperformance should continue for several reasons including P/E multiples and increasing M&A. The piece also discusses product ramp-ups at InterMune (ITMN), Human Genome Sciences (HGSI) and Regneron (REGN). (submitted by Bret Jensen)